Welcome to Dresden Stem Cell Lab!

Prof. Dr. med. Martin Bornhaeuser

 

Principal investigator

Department of Internal Medicine IMB
University Hospital Carl Gustav Carus
Technische Universität Dresden

Fetscherstraße 74
01307 Dresden
Germany

Ph.: +49-351-458 4704
Fax: +49-351-458 5362

martin.bornhaeuser@uniklinikum-dresden.de

Research topic(s):

Allogeneic stem cell transplantation, Cellular therapy, Adoptive immunotherapy, Cell biology of mesenchymal and hematopoietic stem cells, Targeted therapy.

Education:

1986-1993           Study of medicine, Kiel, Germany

1989-1991           Doctoral thesis

2001                    Habilitation for Internal Medicine, Dresden, Germany

Carreer:

1993-1994           Fellowship, Hematology/Oncology, University Hospital, Tübingen, Germany

1994                    Stem Cell Laboratory, Department for Pediatrics, Tübingen, Germany

1995-1998           Internship, University Hospital, Dresden, Germany

1999                    Board Certification for Internal Medicine

2000                    Board Certification for Hematology/Oncology

1998-2003           Senior physician

2004                    Head of Stem Cell Transplant Program, University Hospital, Dresden, Germany

2004                    Endowed C3-Professorship Stem Cell Transplantation, Dresden, Germany

2009                    W3 professor for Translational Biomedical Research, CRTD

2011                    W3 Professor for Hematology/Oncology, University Hospital, Dresden

Other Qualifications:

2002                    Certified Member of the European Society for Medical Oncology

Selectet Publications:

Kräter M, Jacobi A, Otto O, Tietze S, Müller K, Poitz DM, Palm S, Zinna VM, Biehain U, Wobus M, Chavakis T, Werner C, Guck J and Bornhauser, M (2017): Bone marrow niche-mimetics modulate HSPC function via integrin signaling. Scientific Reports. doi:10.1038/s41598-017-02352-5

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhauser M, Ehninger G (2016): Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer J. 6:e386.

Wobus M, Bornhauser M, Jacobi A, Krater M, Otto O, Ortlepp C, Guck J, Ehninger G, Thiede C, Oelschlägel U (2015): Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. Oncotarget. 36, 38804-15

Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schafer-Eckart K, Holler E, Kroger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M (2012): Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 13, 1035-1044.

Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhauser M, Juliusson G, Racil Z, Rowe JM, Russell N, Mohty M, Lowenberg B, Socie G, Niederwieser D, Ossenkoppele GJ (2012): The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat. Rev. Clin. Oncol. 9, 579-590.

Bornhauser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J, Lehmann D, Holig K, Radke J, Tuve S, Wermke M, Wehner R, Jahnisch H, Bachmann MP, Rieber EP, Schetelig J, Ehninger G, Schmitz M (2011): Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 117, 7174-7184.

Bornhauser M, Aringer M, Thiede C (2010): Mixed lymphohematopoietic chimerism and response in Wegener’s granulomatosis. N. Engl. J. Med. 362, 2431-2432.

Bornhauser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hanel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G (2008): Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. Clin. Cancer Res. 14, 5585-5593.